They Thought Hemophilia Was a ‘Lifelong Thing.’ They May Be Wrong. [The New York Times]
BioMarin Pharmaceutical Inc. (BMRN)
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.biomarin.com
Company Research
Source: The New York Times
Experimental gene therapies have yielded promising results in early trials. But the drugs have left some patients wary, worried that success will not last. Image A colored scanning electron micrograph of a blood clot. Hemophilia is defined by an inability to form blood clots, leading to uncontrolled bleeds and chronic pain. Credit Steve Gschmeissner/Science Source Aug. 13, 2018 Scientists are edging closer to defeating a longtime enemy of human health: hemophilia, the inability to form blood clots. After trying for decades to develop a gene therapy to treat this disease, researchers are starting to succeed. In recent experiments, brief intravenous infusions of powerful new treatments have rid patients — for now, at least — of a condition that has shadowed them all their lives. There have been setbacks — years of failed clinical trials and dashed hopes. Just last week, a biotech company reported that gene therapy mostly stopped working in two of 12 patients in
Show less
Read more
Impact Snapshot
Event Time:
BMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
News
- Jean-Jacques Bienaimé Appointed Chairman of the Board at Owkin [Yahoo! Finance]Yahoo! Finance
- New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting [Yahoo! Finance]Yahoo! Finance
- New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics MeetingPR Newswire
- Insider Sell: President, Worldwide R&D Henry Fuchs Sells 35,341 Shares of Biomarin ... [Yahoo! Finance]Yahoo! Finance
- BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer [Yahoo! Finance]Yahoo! Finance
BMRN
Earnings
- 2/22/24 - Beat
BMRN
Sec Filings
- 3/28/24 - Form 144
- 3/20/24 - Form 4
- 3/19/24 - Form 4
- BMRN's page on the SEC website